EC Number   |
Protein Variants |
Reference |
|---|
   7.6.2.2 | A1208V/G521S |
the mutant exhibits a strong synergistic decrease of resistance to fenbuconazole |
733389 |
| 7.6.2.2 | A481G/V482A/M483V/M485V |
the MRP1 mutant shows altered transport activities compared to the wild-type MRP1 |
697583 |
| 7.6.2.2 | A493K/H494Q/S497L/N500S |
the MRP1 mutant shows altered transport activities compared to the wild-type MRP1 |
697583 |
| 7.6.2.2 | A493K/H494Q/S497L/N500S/N506S |
the MRP1 mutant shows altered transport activities compared to the wild-type MRP1 |
697583 |
| 7.6.2.2 | A493K/H494Q/S497L/N506S/T487M/K488R/T489A/Y490F |
the MRP1 mutant shows altered transport activities compared to the wild-type MRP1 |
697583 |
| 7.6.2.2 | A666G |
the mutant shows an uncoupling of ATPase and drug transport and displays a selective loss of resistance to one or more of the tested drugs, the mutant displays a hyperresistant phenotype towards fluconazole comparable to wild type |
696431 |
| 7.6.2.2 | A80C/R741C |
site-directed mutagenesis, cysteines A80C/R741C are close enough to spontaneously form a disulfide bond in the mature protein at the cell surface and trap Pgp in an inactive conformation. Tariquidar is the only P-gp drug substrate or modulator that blocks A80C/R741C crosslinking |
755956 |
| 7.6.2.2 | A980C |
site-directed mutagenesis, the mutant shows altered substrate transport activity and activation by the substrates, e.g. vinblastine and nicardipine, compared to the wild-type enzyme |
696343 |
| 7.6.2.2 | C1056A |
the mutation leads to increased drug susceptibility while the ATPase activity of the mutant remains unaltered |
733248 |
| 7.6.2.2 | C1091A |
the mutation leads to increased drug susceptibility while the ATPase activity of the mutant remains unaltered |
733248 |
